Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Tsimberidou AM, Guenther K, Andersson BS, Mendrzyk R, Alpert A, Wagner C, Nowak A, Aslan K, Satelli A, Richter F, Kuttruff-Coqui S, Schoor O, Fritsche J, Coughlin Z, Mohamed AS, Sieger K, Norris B, Ort R, Beck J, Vo HH, Hoffgaard F, Ruh M, Backert L, Wistuba II, Fuhrmann D, Ibrahim NK, Morris VK, Kee BK, Halperin DM, Nogueras-Gonzalez GM, Kebriaei P, Shpall EJ, Vining D, Hwu P, Singh H, Reinhardt C, Britten CM, Hilf N, Weinschenk T, Maurer D, Walter S. Tsimberidou AM, et al. Among authors: backert l. Cancer Immunol Res. 2023 Jul 5;11(7):925-945. doi: 10.1158/2326-6066.CIR-22-0444. Cancer Immunol Res. 2023. PMID: 37172100 Free PMC article. Clinical Trial.
Pitfalls in HLA Ligandomics-How to Catch a Li(e)gand.
Fritsche J, Kowalewski DJ, Backert L, Gwinner F, Dorner S, Priemer M, Tsou CC, Hoffgaard F, Römer M, Schuster H, Schoor O, Weinschenk T. Fritsche J, et al. Among authors: backert l. Mol Cell Proteomics. 2021;20:100110. doi: 10.1016/j.mcpro.2021.100110. Epub 2021 Jun 12. Mol Cell Proteomics. 2021. PMID: 34129939 Free PMC article.
Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.
Löffler MW, Kowalewski DJ, Backert L, Bernhardt J, Adam P, Schuster H, Dengler F, Backes D, Kopp HG, Beckert S, Wagner S, Königsrainer I, Kohlbacher O, Kanz L, Königsrainer A, Rammensee HG, Stevanović S, Haen SP. Löffler MW, et al. Among authors: backert l. Cancer Res. 2018 Aug 15;78(16):4627-4641. doi: 10.1158/0008-5472.CAN-17-1745. Epub 2018 May 22. Cancer Res. 2018. PMID: 29789417 Free PMC article.
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Rammensee HG, Wiesmüller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bödder J, Schertel JM, Tunger A, Müller L, Kießler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougère C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanović S, Löffler MW. Rammensee HG, et al. Among authors: backert l. J Immunother Cancer. 2019 Nov 15;7(1):307. doi: 10.1186/s40425-019-0796-5. J Immunother Cancer. 2019. PMID: 31730025 Free PMC article.
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.
Nelde A, Kowalewski DJ, Backert L, Schuster H, Werner JO, Klein R, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S, Walz JS. Nelde A, et al. Among authors: backert l. Oncoimmunology. 2018 Feb 14;7(4):e1316438. doi: 10.1080/2162402X.2017.1316438. eCollection 2018. Oncoimmunology. 2018. PMID: 29632711 Free PMC article.
A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.
Backert L, Kowalewski DJ, Walz S, Schuster H, Berlin C, Neidert MC, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Kanz L, Salih HR, Kohlbacher O, Weisel K, Rammensee HG, Stevanovic S, Walz JS. Backert L, et al. Oncotarget. 2017 Jul 4;8(27):43915-43924. doi: 10.18632/oncotarget.14918. Oncotarget. 2017. PMID: 28159928 Free PMC article.
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A, Bichmann L, Kuchenbecker L, Kowalewski DJ, Freudenmann LK, Backert L, Mühlenbruch L, Szolek A, Lübke M, Wagner P, Engler T, Matovina S, Wang J, Hauri-Hohl M, Martin R, Kapolou K, Walz JS, Velz J, Moch H, Regli L, Silginer M, Weller M, Löffler MW, Erhard F, Schlosser A, Kohlbacher O, Stevanović S, Rammensee HG, Neidert MC. Marcu A, et al. Among authors: backert l. J Immunother Cancer. 2021 Apr;9(4):e002071. doi: 10.1136/jitc-2020-002071. J Immunother Cancer. 2021. PMID: 33858848 Free PMC article.
Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.
Barth SM, Schreitmüller CM, Proehl F, Oehl K, Lumpp LM, Kowalewski DJ, Di Marco M, Sturm T, Backert L, Schuster H, Stevanović S, Rammensee HG, Planz O. Barth SM, et al. Among authors: backert l. PLoS One. 2016 Nov 28;11(11):e0167017. doi: 10.1371/journal.pone.0167017. eCollection 2016. PLoS One. 2016. PMID: 27893789 Free PMC article.
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, Fotin-Mleczek M, Hoerr I, Clemens R, von Sonnenburg F. Alberer M, et al. Among authors: backert l. Lancet. 2017 Sep 23;390(10101):1511-1520. doi: 10.1016/S0140-6736(17)31665-3. Epub 2017 Jul 25. Lancet. 2017. PMID: 28754494 Clinical Trial.
22 results